A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study-Reference-Cited by-同舟云学术

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

Published:2017-02-28 Issue:8 Volume:19 Page:1135-1144
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Banerjee Anuradha,Jakacki Regina I.,Onar-Thomas Arzu,Wu Shengjie,Nicolaides Theodore,Young Poussaint Tina,Fangusaro Jason,Phillips Joanna,Perry Arie,Turner David,Prados Michael,Packer Roger J.,Qaddoumi Ibrahim,Gururangan Sridharan,Pollack Ian F.,Goldman Stewart,Doyle Lawrence A.,Stewart Clinton F.,Boyett James M.,Kun Larry E.,Fouladi Maryam

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/19/8/1135/18768744/now282.pdf

Reference42 articles.

1. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009;Neuro Oncol,2012

2. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group;J Clin Oncol,2012

3. Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children’s Oncology Group;Children’s Oncology Group;J Clin Oncol,2008